A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)

BACKGROUND: According to current evidence, the best treatment for fit patients with non-resectable pancreatic cancer (PC) is combination chemotherapy, whereas frail patients are recommended gemcitabine (Gem) monotherapy. Randomized controlled trials in colorectal cancer and a post-hoc analysis of ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasmussen, Louise Skau, Winther, Stine B., Chen, Inna M., Weber, Britta, Ventzel, Lise, Liposits, Gabor, Johansen, Julia Sidenius, Detlefsen, Sönke, Egendal, Ida, Shim, Susy, Christensen, Signe, Pfeiffer, Per, Ladekarl, Morten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273702/
https://www.ncbi.nlm.nih.gov/pubmed/37328835
http://dx.doi.org/10.1186/s12885-023-11035-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273702/
https://www.ncbi.nlm.nih.gov/pubmed/37328835
http://dx.doi.org/10.1186/s12885-023-11035-6

Ejemplares similares